Abeona (ABEO) Officer Sells Shares to Cover Taxes; 350,763 Shares Retained

Rhea-AI Filing Summary

ABEO Form 4 summary: Brendan M. O'Malley, Senior Vice President and Chief Legal Officer of Abeona Therapeutics (ABEO), reported a sale of 9,366 shares of common stock on 09/29/2025 at a weighted average price of $5.3935 per share. After the sale, he beneficially owns 350,763 shares. The filing states the sale was executed to cover tax obligations arising from the vesting of restricted stock awards and that the reported price reflects multiple transactions ranging from $5.35 to $5.46.

Insights

Corporate Governance Expert

TL;DR: Routine tax-covering sale by an officer; not a change in control or policy.

The Form 4 documents an internal liquidity event to satisfy tax obligations tied to restricted stock vesting. The officer retained a substantial holding of 350,763 shares after the sale, which suggests continued alignment with shareholders. The filing includes the required disclosure about weighted-average pricing and offers to provide detailed trade-level pricing on request.

Securities Analyst

TL;DR: Transaction appears administrative rather than signal of material change in view.

The disposition of 9,366 shares at an average of $5.3935 per share is disclosed as to cover taxes, indicating a standard post-vesting sale. The remaining beneficial ownership level is material for governance context but the filing contains no indication of additional sales, loans, or derivative activity. No new operational or financial information is provided.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

O'Malley Brendan M.

(Last) (First) (Middle)

6555 CARNEGIE AVE., 4TH FLOOR

(Street)

CLEVELAND OH 44103

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ABEONA THERAPEUTICS INC. [ ABEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/29/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/29/2025		S(1)		9,366	D	$5.3935(2)	350,763	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.35 to $5.46 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

	/s/ Brendan O'Malley	10/01/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did ABEO insider Brendan O'Malley report on Form 4?

The filing reports a sale of 9,366 shares on 09/29/2025 at a weighted average price of $5.3935 per share to cover tax obligations from vested restricted stock.

How many ABEO shares does Brendan O'Malley own after the sale?

The Form 4 shows he beneficially owns 350,763 shares following the reported transaction.

Why were the shares sold according to the Form 4?

The sale was made to cover tax obligations associated with the vesting of restricted stock awards, as stated in the filing.

What price range were the sold ABEO shares executed at?

Trades were executed at prices ranging from $5.35 to $5.46, with a reported weighted average price of $5.3935.

Does the Form 4 report any derivative transactions for ABEO by this filer?

No. The filing lists only a non-derivative sale of common stock and shows no derivative securities activity.